期刊
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
卷 69, 期 3, 页码 1019-1028出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2008.01.011
关键词
nicorandil; chitosan; hyaluronic acid sodium salt; pectin alginate; interpolymer complex; Imwitor (R) 900 K; matrix tablet
The purpose of this work was to develop an extended release matrix tablet of nicorandil; a freely water soluble drug used in cardiovascular diseases. Chitosan (CH/hyaluronate sodium (HA), pectin (PE) or alginate sodium (AL) interpolyrner complexes (IPCs) were prepared. The optimum IPCs (CH:HA, 40:60), (CH:PE, 30:70) and (CH:AL, 20:80) were characterized by Fourier transform infrared spectroscopy. The IPCs were based oil electrostatic interactions between protonated amine groups of CH and carboxylate groups of HA, PE or AL. Nicorandil matrix tablets were prepared using the optimum IPCs, alone or in combination with Imwitor (R) 900 K. Evaluations Such as weight variation, thickness, content uniformity, friability, disintegration and in vitro release studies were performed. The tablets showed acceptable pharmacotechnical properties and complied with compendial requirements. Results of the dissolution studies revealed that formula F11 (CH:AL, 20:80) IPC:Imwitor (R) 900 K, 3:1) could extend drug release >8 h. Most formulae exhibited non-Fickian diffusion drug release profiles. When compared to the immediate release Ikorel (R) tablet, the duration of effective nicorandil therapeutic concentration from formula F11, in healthy human volunteers, was significantly (P < 0.05) extended from 4 to 8 h with expected lowering in side effects potential. (C) 2008 Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据